Breast Implant Surgery: What You Need to Know — Cost, Top Hospitals & Success Rates | MyMedicPlus

A breast implant is a medical device placed surgically within or beneath the breast tissue to increase breast volume and improve shape. Modern breast implants consist of a silicone elastomer shell filled with cohesive silicone gel (the most widely used globally) or sterile saline solution. The development of fifth-generation cohesive gel implants — whose gel maintains shape stability even if the shell is compromised — has substantially improved safety and naturalness since the initial generation of liquid gel implants used in the 1960s.

Breast implant surgery (augmentation mammaplasty) is the most commonly performed cosmetic surgical procedure in multiple countries and is also performed for breast reconstruction following mastectomy. The procedural decision involves selecting the implant type, volume, shape, surface texture, and surgical approach — decisions made collaboratively between patient and surgeon based on the patient's existing anatomy, desired outcome, lifestyle, and risk preferences. Modern decision-support tools including 3D imaging simulation allow patients to visualise projected outcomes before surgery.

Implants are placed through one of four incision sites: inframammary fold (most common, best access and lowest complication rate), periareolar (lower half of the areola edge), transaxillary (through the armpit), or transumbilical (through the navel — saline only). The pocket is created either under the breast gland (subglandular), under the pectoral muscle (submuscular), or in the dual-plane position (partially above and partially below the muscle) which is the current gold standard for most patients.

The FDA, NICE, and national regulatory agencies worldwide provide comprehensive guidance on breast implant safety. Patients should be registered with their implant manufacturer's registry, maintain records of their implant brand and model number, and adhere to recommended surveillance imaging protocols for long-term safety monitoring.

Breast implants are used cosmetically for hypomastia (small, underdeveloped breasts), breast asymmetry correction, restoration of post-pregnancy or post-weight-loss volume deflation, and as part of gender-affirming surgery for trans women when hormone-induced breast development is insufficient. In reconstructive surgery, implants are used after mastectomy for breast cancer — either in a direct-to-implant (DTI) reconstruction in appropriate candidates, or following tissue expander placement with delayed exchange to a permanent implant.

Implants may also be indicated for Poland syndrome (congenital absence of the pectoralis muscle and associated chest wall and breast deformity), tuberous breast correction (combined with scoring of constricted lower pole), and correction of congenital breast asymmetry. In all these contexts, the implant serves to restore or create a breast mound that the patient's own tissue cannot provide. Each indication has specific technique requirements — reconstruction implants, for example, must work within the constraints of available tissue coverage, prior radiation field effects, and potentially impaired wound healing.

For cosmetic augmentation: women aged 18+ (or 22+ for silicone in the USA) who are at stable weight, in good health, non-smoking, with specific realistic goals, and who understand that breast implants are not lifetime devices requiring future monitoring and potential replacement. Patients should have no undiagnosed breast masses — pre-operative imaging is recommended for women over 40 or those with a family history of breast cancer. Adequate breast tissue must be present for implant coverage; very lean patients with minimal native tissue may need submuscular placement to reduce implant visibility and palpability.

Relative contraindications include active autoimmune or connective tissue diseases (increased capsular contracture risk), prior breast radiation, prior breast surgery that may compromise blood supply, and significant ptosis requiring concomitant mastopexy. Absolute contraindications include active breast or systemic infection, undiagnosed breast pathology, pregnancy or breastfeeding, and insufficient skin envelope for coverage. Patients on bisphosphonate therapy should disclose this, as dental implant (not breast) interactions are the more relevant concern — bisphosphonates are not contraindicated for breast implants specifically, though they are for dental implants.

Silicone cohesive gel implants are the global standard, available from major manufacturers (Allergan Natrelle, Mentor MemoryGel, Sientra, Motiva, Sebbin). They come in round and anatomical (teardrop) shapes, smooth and textured surfaces, and a range of profiles and volumes. Round smooth implants in the 250-400cc range represent the most frequently placed implants globally, offering consistent results with low complication rates. Saline implants (filled post-insertion, allowing smaller incisions) have a firmer feel, are detectable on rupture immediately (instant deflation), and contain only sterile saltwater — preferred by some patients concerned about gel migration.

The dual-plane technique is the current gold standard for most primary augmentation: placing the upper implant pole behind the pectoralis muscle (providing natural soft tissue coverage) and the lower pole in a subglandular position (allowing natural lower pole expansion). This reduces capsular contracture rates compared to full subglandular placement and avoids implant animation deformity with complete submuscular placement. Textured implants provide rotational stability (important for shaped anatomical implants) but carry a higher BIA-ALCL risk than smooth implants. The FDA recommendation since 2019 is that patients are counselled about BIA-ALCL risk and that smooth implants are considered as the safer option where anatomical positioning is not required.

The operating surgeon reviews the patient's complete medical history, current medications, and desired outcomes before finalising the surgical plan. Preoperative digital photography and computer simulation allow the surgeon and patient to align expectations and visualise potential results. Anaesthetic choice — general anaesthesia or intravenous sedation with local anaesthesia — is decided in consultation with the anaesthesiologist based on procedure complexity, patient health status, and patient preference. Postoperative care instructions, including wound care, activity restrictions, and follow-up scheduling, are provided in written form before surgery.

Women who undergo breast implant surgery report high satisfaction rates — consistently above 85% in prospective series at 3-5 years. Benefits include increased breast volume, improved breast shape and projection, correction of asymmetry, enhanced body image, increased confidence, and a greater sense of femininity. For women with post-partum breast deflation, implants restore the breast contour that existed before pregnancy, completing the physical aspect of post-pregnancy body restoration.

For breast cancer patients undergoing mastectomy, implant-based reconstruction restores the breast mound without requiring harvest of muscle or skin from another body site (unlike autologous reconstruction). The ability to wake from mastectomy with a breast mound in place (via direct-to-implant reconstruction) significantly reduces the psychological trauma of breast loss for appropriately selected patients. Patient-reported quality-of-life outcomes (BREAST-Q) demonstrate meaningful improvements in breast satisfaction, sexual wellbeing, and psychosocial wellbeing that are maintained at 3 and 5 years.

The most important risks patients must understand before breast implant surgery are: capsular contracture (hardening of the fibrous tissue around the implant, requiring reoperation in 5-15% of cases at 10 years); implant rupture (approximately 10-15% of silicone implants at 10 years — 'silent rupture' only detectable on MRI); asymmetry and revision surgery (10-15% of patients require additional surgery within 10 years for various reasons); and altered nipple sensation (usually temporary, resolves in 3-12 months in most patients).

BIA-ALCL (breast implant-associated anaplastic large cell lymphoma) is a rare but important risk, primarily associated with textured macrotextured implants. The FDA estimates risk at 1:2,207 for Allergan Biocell textured implants (the brand voluntarily recalled in 2019) and lower rates for other textured implants. Smooth implants have minimal BIA-ALCL risk. BIA-ALCL presents as late persistent seroma and is usually cured by complete capsulectomy. Breast implant illness (BII) — systemic symptoms attributed to implants — is reported by some patients; causation is debated but explantation often leads to symptom improvement. All risks should be discussed and documented in informed consent.

Post-operative care includes a surgical bra worn day and night for 2-4 weeks, light activity from day 3-5, avoidance of heavy lifting and chest exercises for 4-6 weeks, and avoidance of strenuous sport for 6 weeks. Swelling and implant high-riding position normalise over 3-6 months as the pocket stretches and the implant settles. Final result assessment is best performed at 6 months.

Long-term surveillance is critically important for implant safety. The FDA recommends: first MRI at 5-6 years post-implantation to detect silent rupture of silicone implants, then every 2-3 years. Patients should register with their implant manufacturer's tracking registry and keep the implant identification card provided at surgery. Monthly breast self-examination and annual clinical examination by a physician should be maintained alongside standard breast cancer screening. Any new persistent seroma (fluid swelling) around the implant, especially developing months or years after surgery, should prompt urgent evaluation to rule out BIA-ALCL. All post-implant mammograms should be performed with Eklund displacement views.

Breast implant surgery (augmentation) in the USA costs USD 6,000-12,000 including surgeon, anaesthesia, facility, and implant costs (implants alone are USD 1,000-2,500 per pair). In the UK, private augmentation costs GBP 4,500-8,000. Premium implant brands and high-definition techniques carry higher costs. Reconstruction implants after mastectomy may be covered by insurance (Women's Health and Cancer Rights Act mandates coverage in the USA for post-mastectomy reconstruction).

Medical tourism for breast implant surgery offers savings of 40-65% at accredited international centres. Turkey leads the European market with all-inclusive packages at USD 3,000-5,500 using major implant brands. Czech Republic, Hungary, and Poland offer comparable quality at USD 3,500-6,000 for European patients. Thailand (USD 4,000-7,000) and India (USD 2,000-3,500) serve Asian and Australian medical tourism markets. International patients should ensure the implant brand and model used at their chosen centre are the same FDA-approved or CE-marked products available in their home country, allowing continuity of surveillance and care after returning home.

Autologous fat transfer (lipofilling) to the breasts provides natural augmentation of half to one cup size using the patient's own harvested fat — there are no implant-related risks, but volume increase is limited, fat reabsorption is variable (30-50% in first 3 months), and multiple sessions may be needed. Vampire breast lift uses platelet-rich plasma (PRP) injections into the breast — this is an unproven technique with no high-quality evidence and should be approached with caution.

Non-surgical options (padded bras, breast inserts, vacuum suction devices) provide appearance enhancement without risks. For patients considering explantation, options include implant removal with mastopexy, removal with fat transfer, or removal alone — outcomes depend heavily on breast tissue volume, skin elasticity, and degree of ptosis. Patients considering these alternatives should consult a board-certified plastic surgeon to discuss the trade-offs specific to their anatomy.